# Ultragenyx Pharmaceutical Inc. (RARE)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $2.36B  
**Price:** $23.98 (+4.40%)

> Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Ultragenyx Pharmaceutical Inc. currently markets medicines for conditions such as X-linked hypophosphatemia, mucopolysaccharidosis VII, and certain metabolic disorders, while also maintaining a pipeline across bone, endocrine, metabolic, muscle, and central nervous system disease areas. The company works to address serious, often debilitating disorders with limited treatment options through multiple drug modalities, including biologics and small molecules. Its business centers on identifying unmet medical needs in rare disease and delivering specialized treatments to patients, healthcare providers, and medical institutions. Headquartered in Novato, California, and founded in 2010, Ultragenyx Pharmaceutical Inc. plays a notable role in the rare-disease biopharmaceutical market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $673M | — | -$535M | -$575M | $-5.83 |
| 2024 | $560M | — | -$536M | -$569M | $-6.29 |
| 2023 | $434M | — | -$569M | -$607M | $-8.25 |
| 2022 | $363M | — | -$649M | -$707M | $-10.12 |
| 2021 | $351M | — | -$382M | -$454M | $-6.70 |
| 2020 | $271M | — | -$330M | -$187M | $-3.07 |
| 2019 | $104M | — | -$424M | -$403M | — |
| 2018 | $51M | $50M | -$371M | -$198M | — |
| 2017 | $3M | $3M | -$329M | -$302M | — |
| 2016 | $133,000 | — | -$248M | -$246M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.53B | $1.60B | -$80M | $421M | — |
| 2024 | $1.50B | $1.24B | $255M | $174M | — |
| 2023 | $1.49B | $1.22B | $275M | $214M | — |
| 2022 | $1.55B | $1.19B | $352M | $133M | — |
| 2021 | $1.52B | $600M | $923M | $308M | — |
| 2020 | $1.76B | $605M | $1.15B | $714M | — |
| 2019 | $1.14B | $482M | $654M | $434M | — |
| 2018 | $720M | $111M | $609M | $113M | — |
| 2017 | $491M | $107M | $383M | $100M | — |
| 2016 | $541M | $67M | $474M | $161M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$466M | $6M | -$472M |
| 2024 | -$414M | $7M | -$421M |
| 2023 | -$475M | $44M | -$519M |
| 2022 | -$380M | $116M | -$497M |
| 2021 | -$339M | $73M | -$412M |
| 2020 | -$132M | $44M | -$176M |
| 2019 | -$345M | $25M | -$370M |
| 2018 | -$291M | $4M | -$295M |
| 2017 | -$254M | $3M | -$257M |
| 2016 | -$161M | $10M | -$171M |

Source: [CompaniesByCap](https://companiesbycap.com/company/RARE)